Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2088-2100
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2088
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2088
Table 2 Comparison of patient characteristics, tumor markers, and microbiomes
| Benign group (n = 22) | Malignant group (n = 12) | P value | |
| Age, yr (mean ± SD) | 63.0 ± 12.2 | 73.0 ± 8.3 | 0.016 |
| Sex (male/female) | 8/14 | 4/8 | 1.0 |
| Reduction in body weight ≥ 5 kg within 6 mo before duodenal juice sampling, n (%) | 1 (4.5) | 2 (16.7) | 0.28 |
| Intake of proton pump inhibitors, n (%) | 4 (18.2) | 2 (16.7) | 1.0 |
| CA19-9, U/mL, median (range) | 5.4 (2.0-54.8) | 22.8 (2.0-9893.2) | 0.03 |
- Citation: Sugimoto M, Abe K, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Dysbiosis of the duodenal microbiota as a diagnostic marker for pancreaticobiliary cancer. World J Gastrointest Oncol 2021; 13(12): 2088-2100
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2088.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2088